Cardiol Therapeutics (TSE:CRDL) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Cardiol Therapeutics Inc., a clinical-stage life sciences company, has announced their virtual Annual General and Special Meeting of Shareholders to be webcasted on June 26, 2024. The company, known for its development of anti-inflammatory and anti-fibrotic therapies for heart disease, is advancing clinical studies of its lead drug, CardiolRx™, with FDA approval for trials in pericarditis and myocarditis. Cardiol is also progressing with CRD-38, a new drug formulation aimed at treating heart failure, a major cause of mortality and hospitalization.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
